Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.

Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S.

J Hepatol. 2013 Apr;58(4):792-800. doi: 10.1016/j.jhep.2012.10.027. Epub 2012 Nov 5. Review.

PMID:
23137766
[PubMed - indexed for MEDLINE]
Free Article
2.

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.

Seden K, Back D.

Curr Opin HIV AIDS. 2011 Nov;6(6):514-26. doi: 10.1097/COH.0b013e32834b54dc. Review.

PMID:
22001895
[PubMed - indexed for MEDLINE]
3.

Review and management of drug interactions with boceprevir and telaprevir.

Kiser JJ, Burton JR, Anderson PL, Everson GT.

Hepatology. 2012 May;55(5):1620-8. doi: 10.1002/hep.25653. Review.

PMID:
22331658
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The importance of drug-drug interactions in the DAA era.

Back D, Else L.

Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S343-8. doi: 10.1016/j.dld.2013.07.008. Review.

PMID:
24091114
[PubMed - indexed for MEDLINE]
5.

Pharmacokinetics of new oral hepatitis C antiviral drugs.

Vispo E, Barreiro P, Soriano V.

Expert Opin Drug Metab Toxicol. 2013 Jan;9(1):5-16. doi: 10.1517/17425255.2013.729577. Epub 2012 Oct 25. Review.

PMID:
23094639
[PubMed - indexed for MEDLINE]
6.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
[PubMed - indexed for MEDLINE]
7.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373
[PubMed - indexed for MEDLINE]
8.

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.

Lam JT, Jacob S.

Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9. doi: 10.2146/ajhp110500. Review.

PMID:
23230035
[PubMed - indexed for MEDLINE]
9.

Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

Naggie S, Sulkowski MS.

Gastroenterology. 2012 May;142(6):1324-1334.e3. doi: 10.1053/j.gastro.2012.02.012. Review.

PMID:
22537439
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Future of hepatitis C therapy: development of direct-acting antivirals.

Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS. 2011 Nov;6(6):508-13. doi: 10.1097/COH.0b013e32834b87f8. Review.

PMID:
21897228
[PubMed - indexed for MEDLINE]
11.

Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.

Rodríguez-Torres M.

Curr Opin Infect Dis. 2013 Feb;26(1):50-7. doi: 10.1097/QCO.0b013e32835c2027. Review.

PMID:
23242341
[PubMed - indexed for MEDLINE]
12.

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.

Teixeira R, Nascimento Yde A, Crespo D.

Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204. doi: 10.1016/j.bjid.2012.10.010. Epub 2013 Mar 9. Review.

PMID:
23490868
[PubMed - indexed for MEDLINE]
Free Article
13.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

PMID:
22296568
[PubMed - indexed for MEDLINE]
14.

Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.

Krook AL, Stokka D, Heger B, Nygaard E.

Eur Addict Res. 2007;13(4):216-21.

PMID:
17851243
[PubMed - indexed for MEDLINE]
15.

Hepatitis C: management of side effects in the era of direct-acting antivirals.

Gaetano JN, Reau N.

Curr Gastroenterol Rep. 2013 Jan;15(1):305. doi: 10.1007/s11894-012-0305-1. Review.

PMID:
23269576
[PubMed - indexed for MEDLINE]
16.

Telaprevir: pharmacokinetics and drug interactions.

Garg V, Kauffman RS, Beaumont M, van Heeswijk RP.

Antivir Ther. 2012;17(7):1211-21. doi: 10.3851/IMP2356. Epub 2012 Sep 7. Review.

PMID:
22954756
[PubMed - indexed for MEDLINE]
17.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
18.

Treatment failure with new hepatitis C drugs.

Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P.

Expert Opin Pharmacother. 2012 Feb;13(3):313-23. doi: 10.1517/14656566.2012.653341. Epub 2012 Jan 14. Review.

PMID:
22242928
[PubMed - indexed for MEDLINE]
19.

Telaprevir: changing the standard of care of chronic hepatitis C.

Rajani AK, Ravindra BK, Dkhar SA.

J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493. Review.

PMID:
23525057
[PubMed - indexed for MEDLINE]
Free Article
20.

[Quality assurance in patient addiction treated with drug substitution].

[No authors listed]

Krankenpfl J. 2005;43(7-10):248. German. No abstract available.

PMID:
16515317
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk